Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.

Saved in:
Bibliographic Details
Title: Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
Authors: Arora S; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Deshmukh I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jabbour J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Source: Cancer [Cancer] 2025 Aug 15; Vol. 131 (16), pp. e70032.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.70032